Mepolizumab (Nucala) for Severe Asthma: A Complete Patient Guide

What Is Mepolizumab?

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), a key signaling protein in the immune cascade that produces, activates, and prolongs the survival of eosinophils — a type of white blood cell at the center of severe asthma inflammation.

Marketed under the brand name Nucala, mepolizumab was developed by GSK (GlaxoSmithKline) and received FDA approval in November 2015 for severe eosinophilic asthma in adults. It has since received additional approvals for eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP) — a common comorbidity in severe asthma patients.

Mepolizumab belongs to a class called biologic therapies — medicines derived from living cells that are engineered to interrupt a specific molecular target rather than suppressing the immune system broadly. This precision is what distinguishes biologics from oral corticosteroids, which have wide-ranging systemic effects.

How IL-5 Blockade Works

To understand why mepolizumab is effective in a specific subset of asthma patients, it helps to trace the inflammatory pathway it interrupts.

The Eosinophil Problem in Severe Asthma

In healthy airways, eosinophils play a role in fighting parasitic infections. In eosinophilic asthma, however, the immune system mounts an inappropriate eosinophilic response to environmental triggers — allergens, pollutants, respiratory infections, or in some cases no identifiable trigger at all (non-allergic eosinophilic asthma).

Activated eosinophils release toxic granule proteins including major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil peroxidase (EPO). These chemicals directly damage the airway epithelium, trigger bronchospasm, promote mucus hypersecretion, and amplify the underlying inflammatory cycle. The result is airway hyperresponsiveness, progressive remodeling, and recurrent exacerbations that do not respond adequately to standard controller therapy.

Where IL-5 Enters the Picture

Interleukin-5 is the primary cytokine that regulates eosinophil biology. It signals the bone marrow to produce more eosinophils, promotes their release into circulation, activates them in the airway mucosa, and prolongs their survival by blocking programmed cell death (apoptosis). Without IL-5 signaling, the eosinophil burden in the airways drops significantly.

Mepolizumab binds directly to soluble IL-5 with high specificity and affinity, preventing it from engaging the IL-5 receptor (IL-5R) on the eosinophil surface. The result: eosinophil production is curtailed at the bone marrow level, circulating eosinophil counts fall within weeks, and airway tissue eosinophilia diminishes over subsequent months. In clinical trials, mepolizumab reduced blood eosinophil counts by approximately 84% from baseline within four weeks of the first injection.

Why This Matters for Asthma Control

Fewer airway eosinophils means less epithelial damage, less mucus plugging, and a reduced frequency of the acute inflammatory flares that drive exacerbations. Importantly, because mepolizumab targets only IL-5 — not the broader immune response — it does not impair host defense against bacterial or viral infections in the way that systemic corticosteroids do. Patients on mepolizumab do not face the immunosuppression risks associated with oral prednisone used for the same purpose.

Who Qualifies for Mepolizumab?

Mepolizumab is not appropriate for all patients with asthma. FDA approval and clinical guidelines from the Global Initiative for Asthma (GINA) define clear eligibility criteria.

FDA-Approved Indication

Mepolizumab is approved as an add-on maintenance treatment for patients with:

• Age 6 years and older (adult dosing 100 mg SC; pediatric 6–11 years 40 mg SC)
• Severe asthma at GINA Step 4 or 5 (high-dose ICS plus LABA or additional controllers)
• An eosinophilic phenotype confirmed by blood eosinophil count

Eosinophil Threshold

Blood eosinophil count is the primary biomarker used to predict response. GINA 2025 and clinical practice generally support initiating mepolizumab when:

• Blood eosinophils are at or above 150 cells/mcL at the time of initiation, or
• Blood eosinophils have been 300 cells/mcL or higher at any point in the preceding 12 months (reflecting natural variability due to oral corticosteroid use, which suppresses eosinophil counts)

Higher eosinophil counts (≥300–500 cells/mcL) predict a stronger and more consistent treatment response. However, even patients with moderate eosinophilia who have frequent exacerbations and oral corticosteroid dependence may benefit substantially.

Other Eligibility Factors

Patients most likely to be offered mepolizumab typically have one or more of the following:

• Two or more asthma exacerbations requiring systemic corticosteroids in the prior year
• One or more exacerbations requiring emergency department visit or hospitalization
• Chronic oral corticosteroid (OCS) use to maintain baseline control
• Documented FeNO (fractional exhaled nitric oxide) ≥25 ppb, consistent with type 2 airway inflammation
• Co-existing eosinophilic conditions: nasal polyps, AERD (aspirin-exacerbated respiratory disease), eosinophilic esophagitis

Who Is Not Eligible

Mepolizumab is not indicated for relief of acute bronchospasm or acute asthma attacks, nor for non-eosinophilic asthma phenotypes. It is also not suitable for patients whose asthma is primarily driven by allergic (IgE-mediated) mechanisms without significant eosinophilia — different biologic agents may be more appropriate in those cases. Your physician will review your complete phenotype before recommending any specific biologic.

Clinical Trial Evidence for Mepolizumab

The approval of mepolizumab was supported by a robust clinical trial program. The key pivotal studies are summarized below.

The DREAM Trial

DREAM (Dose Ranging Efficacy and Safety With Mepolizumab) was a Phase 2b randomized, double-blind, placebo-controlled trial published in The Lancet (2012) enrolling 621 patients with severe eosinophilic asthma. Patients received intravenous mepolizumab at 75 mg, 250 mg, or 750 mg, or placebo, every four weeks for 52 weeks.

Key findings:

• All mepolizumab doses significantly reduced the rate of clinically significant exacerbations versus placebo
• The 75 mg IV group showed a 48% reduction in exacerbation rate
• Blood eosinophils fell by approximately 84% across all dose groups within the first four weeks
• Benefit was most pronounced in patients with blood eosinophils ≥500 cells/mcL

The MENSA Trial

MENSA (Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma) was the Phase 3 pivotal trial published in the New England Journal of Medicine (2014), enrolling 576 patients. Patients were randomized to mepolizumab 75 mg IV, 100 mg subcutaneous (SC), or placebo every four weeks for 32 weeks.

Key findings:

• IV group: 47% reduction in exacerbation rate vs. placebo (rate ratio 0.53, 95% CI 0.44–0.64)
• SC 100 mg group: 53% reduction in exacerbation rate vs. placebo (rate ratio 0.47, 95% CI 0.39–0.58)
• Emergency visits and hospitalizations reduced by approximately 32% in the SC group
• FEV₁ improved by a mean of 98 mL from baseline in the SC group
• St. George Respiratory Questionnaire (SGRQ) scores improved significantly, reflecting meaningful quality-of-life gains

The subcutaneous 100 mg dose achieved marginally better efficacy than the intravenous formulation and became the approved commercial dose.

The SIRIUS Trial (OCS Sparing)

SIRIUS specifically addressed whether mepolizumab could reduce chronic oral corticosteroid (OCS) use — critical given the serious long-term toxicity of OCS therapy (diabetes, osteoporosis, adrenal suppression, cataracts, hypertension, weight gain). Published in NEJM (2014), SIRIUS enrolled 135 OCS-dependent patients randomized to mepolizumab 100 mg SC or placebo every four weeks for 24 weeks while investigators attempted to systematically reduce OCS dose.

Key findings:

• Mepolizumab group achieved a median 50% reduction in OCS dose vs. 0% in the placebo group
• 23% of mepolizumab patients were able to eliminate OCS entirely vs. 11% on placebo
• Exacerbation rates were 32% lower in the mepolizumab group

The SIRIUS data established mepolizumab as an OCS-sparing agent — a particularly important benefit for patients who have sustained steroid-related organ damage from years of maintenance prednisone use.

Long-Term Safety: COSMOS and COLUMBA

The COSMOS and COLUMBA open-label extension studies followed patients for up to 4.5 years of continuous mepolizumab therapy. Results showed that exacerbation rate reduction was maintained over long-term treatment, with no new safety signals and no evidence of tachyphylaxis. Blood eosinophil suppression was consistent throughout the treatment period.

Real-World Evidence

Post-marketing observational studies have generally confirmed the trial findings. A 2021 analysis published in Annals of Allergy, Asthma & Immunology found that approximately 60–70% of patients treated with mepolizumab in real-world practice achieved a meaningful reduction in exacerbation rates, with a subset achieving complete exacerbation freedom in the first year of therapy.

Dosing and Administration

Approved Dose

For adults and adolescents 12 years and older with severe eosinophilic asthma: 100 mg subcutaneous injection every four weeks, administered into the upper arm, thigh, or abdomen. For children 6–11 years: 40 mg SC every four weeks.

Where Injections Are Given

Mepolizumab injections are typically administered in a physician's office for the first two to three doses while the clinical team confirms tolerability. Many patients subsequently qualify for home self-injection using the Nucala autoinjector device, which does not require reconstitution. Your provider will train you or a caregiver on proper injection technique before transitioning to home administration.

Timing and Missed Doses

The four-week injection interval should be maintained as consistently as possible. If a dose is missed, it should be administered as soon as practicable, and the schedule reset from that date. Mepolizumab should not be used to treat acute asthma attacks — patients should continue using their short-acting bronchodilator rescue inhaler during exacerbations and seek emergency care if symptoms are severe.

Concomitant Therapy

Mepolizumab is an add-on maintenance therapy. It is initiated in addition to existing controller medications (ICS, LABA, LAMA, LTRA), not as a replacement. Physicians typically continue existing controller therapy at the same dose for at least the first 3–6 months while assessing biologic response, then consider stepdown if significant clinical improvement is documented.

Duration of Therapy

Mepolizumab is an ongoing maintenance treatment, not a curative course. Clinical guidelines suggest reassessment of biologic response at 12–16 weeks after initiation, then annually. If a patient is responding well, treatment is continued indefinitely. If response is inadequate after a fair trial, a phenotyping review and potential switch to an alternative biologic is warranted.

Side Effects and Safety Profile

Mepolizumab has a well-characterized safety profile developed across more than a decade of clinical use. It is generally well tolerated.

Common Side Effects (Reported in ≥3% of Patients)

• Injection site reactions: pain, redness, swelling, burning at the injection site — typically mild and transient, occurring in approximately 8% of patients
• Headache (19%)
• Back pain (5%)
• Fatigue (5%)
• Influenza-like symptoms: mild fever, myalgia (5%)
• Upper respiratory tract infections — similar incidence to placebo in trials

Hypersensitivity Reactions

Systemic allergic reactions and anaphylaxis have been reported rarely with mepolizumab. These reactions typically occur within hours of injection. For this reason, the first few doses are generally administered in a clinical setting where epinephrine and resuscitation equipment are available. Patients should seek immediate medical attention if they experience urticaria, facial swelling, difficulty breathing, or hypotension after an injection.

Herpes Zoster

Clinical trials identified a slightly higher rate of herpes zoster (shingles) in mepolizumab-treated patients compared to placebo (approximately 2% vs. less than 1%). Physicians may recommend shingles vaccination (Shingrix, two-dose series) prior to or early in mepolizumab therapy, particularly for patients over 50 years of age.

Parasitic Infections

Because eosinophils contribute to defense against parasitic infections, mepolizumab carries a theoretical risk of increased susceptibility to helminth (intestinal worm) infections. This is primarily relevant for patients who travel to or reside in endemic regions. Patients with pre-existing parasitic infections should be treated and cleared before initiating mepolizumab.

Pregnancy and Lactation

There are limited data on mepolizumab use during pregnancy. Monoclonal antibodies cross the placenta in the second and third trimesters. Mepolizumab should be used during pregnancy only if the expected benefit outweighs the potential risk. A pregnancy registry (EXPECT) is available for patients who receive mepolizumab during pregnancy. Patients considering conception should discuss the risk-benefit assessment with their pulmonologist. It is unknown whether mepolizumab is present in human breast milk.

Mepolizumab vs. Other Biologics for Severe Asthma

Several biologic agents are now FDA-approved for severe asthma, each targeting a different molecular mechanism. The comparison below is an educational overview; the optimal biologic for an individual patient depends on their specific phenotype, comorbidities, and clinical history. Always consult your physician before making treatment decisions.

Mepolizumab vs. Benralizumab

Both target the IL-5 pathway but at different points. Mepolizumab binds the IL-5 ligand, while benralizumab (Fasenra) binds the IL-5 receptor alpha subunit and additionally depletes eosinophils through antibody-dependent cellular cytotoxicity (ADCC). Benralizumab's every-8-week dosing interval after the induction phase is a practical advantage for some patients. Head-to-head comparative data is limited; choice between them often reflects patient preference, comorbidity profile, insurance coverage, and access to self-administration.

Mepolizumab vs. Dupilumab

Dupilumab targets the IL-4/IL-13 axis and has demonstrated benefit across a broader range of type 2 asthma patients, including those with moderate disease and lower eosinophil counts. Dupilumab also holds the broadest approved indication set, spanning atopic dermatitis, CRSwNP, prurigo nodularis, and eosinophilic esophagitis. For patients with multiple type 2 atopic conditions, dupilumab may address more comorbidities with a single agent. Mepolizumab is more narrowly eosinophil-targeted and may be preferred when eosinophilia is the dominant feature and OCS-sparing is a priority.

Mepolizumab vs. Tezepelumab

Tezepelumab (Tezspire) blocks TSLP, an upstream alarmin cytokine that sits above IL-4, IL-5, IL-13, and IgE in the inflammatory cascade. Because it acts at this earlier point, tezepelumab has demonstrated efficacy even in patients with low blood eosinophil counts where anti-IL-5 agents show diminished benefit. For patients with a non-eosinophilic or mixed inflammatory profile, tezepelumab may be a more appropriate first choice.

What to Expect at Your First Visit

Initial Consultation

Dr. Hull will review your complete asthma history, including age of onset, current and previous medications, exacerbation frequency and severity, emergency care utilization, and any history of oral corticosteroid courses or dependency. He will also ask about comorbidities that influence biologic selection: allergic rhinitis, nasal polyps, atopic dermatitis, eosinophilic esophagitis, GERD, and anxiety or depression (which are associated with worse asthma control independent of inflammation).

Diagnostic Testing

Several tests help characterize your asthma phenotype and establish eligibility for specific biologics:

• Spirometry with bronchodilator reversibility — measures FEV₁, FVC, and the reversibility of airflow obstruction
• Complete blood count with differential — establishes current blood eosinophil count
• FeNO (fractional exhaled nitric oxide) testing — measures airway eosinophilic inflammation directly; results above 25 ppb support type 2 phenotype
• Total IgE and allergen-specific IgE panel — relevant if allergic asthma or omalizumab candidacy is being evaluated
• Chest imaging (if not recently performed) — to rule out structural pathology, bronchiectasis, or other mimics

Treatment Decision and Prior Authorization

If you qualify for mepolizumab, Dr. Hull's office will submit a prior authorization request to your insurance carrier. Most commercial insurers and Medicare Part D cover mepolizumab for patients who meet documented criteria. The prior authorization process typically takes 1–3 weeks. For patients who face coverage gaps or high cost-sharing, GSK's Nucala patient support program (TOGETHER with GSK) offers copay assistance and a free trial period for eligible commercially insured patients.

First Injection Visit

Your first injection is administered in the clinic. Staff will observe you for at least 30 minutes post-injection. The majority of patients experience no immediate reaction. Injection site discomfort, if present, is typically brief. You will receive written instructions on what to watch for and when to call the office versus seek emergency care.

Follow-Up and Response Assessment

A follow-up visit is typically scheduled 12–16 weeks after initiating mepolizumab. At this visit, Dr. Hull will review your exacerbation diary, rescue inhaler use frequency, and any changes in symptom burden. Blood eosinophil count and FeNO will be repeated to confirm the expected pharmacodynamic response. Spirometry will also be reassessed. If response is confirmed and well-tolerated, therapy continues; discussions about OCS tapering (if applicable) can begin at this point.

Severe Asthma Care in South Florida

South Florida presents a distinctive set of challenges for patients with severe or difficult-to-treat asthma. Year-round high humidity and warm temperatures support persistent mold growth and dust mite populations. Florida's subtropical climate means there is no off season for common aeroallergens — grass pollen peaks in spring but persists into autumn, weed pollen follows a second peak in fall, and cockroach allergen is consistently elevated in urban Broward County housing. Ozone levels during summer months regularly exceed the 70 ppb EPA threshold in Fort Lauderdale and surrounding areas on hot, stagnant-air days.

For patients with eosinophilic asthma, this persistent allergen and pollutant burden means airway inflammation is rarely given the opportunity to fully resolve between exacerbations. Biologic therapy that reduces the underlying eosinophilic drive can be particularly transformative in this environment — not because it changes the outdoor environment, but because it reduces the airway's hyperreactive response to it.

Advanced Asthma Clinic in Plantation, FL is the practice of Dr. Frank Hull, MD, a board-certified pulmonologist with more than 20 years of pulmonary research experience, including participation in multiple biologic therapy clinical trials. Dr. Hull has extensive experience in phenotyping patients with severe asthma, selecting the appropriate biologic agent, managing the transition from OCS dependence to biologic-controlled disease, and monitoring long-term responses.

Patients traveling from throughout Broward County — Fort Lauderdale, Hollywood, Pompano Beach, Coral Springs, Miramar, Pembroke Pines, Deerfield Beach, and surrounding communities — are seen at the Plantation clinic.

Frequently Asked Questions